Background: We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir. Methods: This was a three-way crossover study in 12 healthy male participants treated with bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) alone or in combination for 9.5 days. 
Pulmonary arterial hypertension (PAH) is a lifethreatening complication of infection with HIV and is observed in approximately 0.5% of patients with HIV infection [1] [2] [3] . In patients with PAH, arterial endothelin-1 levels in the lung are markedly increased [4] and endothelin-1 levels correlate with the severity of the disease [5] . This leads to vasoconstriction and proliferation of vascular smooth muscle cells. In HIV patients, stimulation of endothelin-1 synthesis by HIV type-1 (HIV-1) envelope glycoprotein 120 might contribute to significantly increased endothelin-1 levels [1, 3] .
Bosentan is a dual endothelin-1 receptor antagonist and is approved for treatment of patients with PAH New York Heart Association (NYHA) functional classes II-IV in the US, and patients with NYHA classes II and III in Europe [6, 7] .
Clinical studies in patients with HIV-associated PAH showed that bosentan given against a background of highly active antiretroviral therapy (HAART) improved clinical and haemodynamic parameters [3, 8] , whereas good survival was noted upon long-term treatment [9] . Antiretroviral treatment effectiveness was not influenced as the number of patients with undetectable viral load or CD4 + T-lymphocyte count <200 cells/mm 3 did not change with bosentan treatment [8] . The management of HIV-related PAH with bosentan was reviewed recently [10] , giving recommendations for treatment of HIV-related PAH.
Bosentan is metabolized by cytochrome P450 (CYP) isoenzymes, CYP3A4 and CYP2C9, with the pharmacologically active Ro 48-5033 being the major metabolite. Bosentan is not only a substrate for these 
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isoenzymes, but also induces their transcription [11] . Drug-drug interactions between bosentan and ketoconazole, rifampicin, glibenclamide and tadalafil were investigated in vivo [12] [13] [14] [15] . A recent in vitro study identified bosentan as a substrate of the human organic anion transporting polypeptides (OATP), OATPB1 and OATPB3, transporter proteins that mediate the uptake of substances into hepatocytes [16] . Inhibition of OATPs by, for example, sildenafil and cyclosporine A, might lead to increased exposure to bosentan [17, 18] . Ritonavir-boosted protease inhibitors have contributed to major improvements in the management of HIV infection [19, 20] . Lopinavir is an inhibitor of the HIV-1 and HIV type-2 proteases. It is metabolized predominantly by CYP3A4, but is also an inducer of this isoenzyme [21] . To achieve drug concentrations sufficient to suppress HIV replication, it is given together with low (booster) doses of the protease inhibitor, ritonavir, a strong CYP3A4 inhibitor [22] . In vitro studies showed that ritonavir also inhibits the transporter protein OATP1B1 [23] .
Pharmacokinetic interactions between bosentan and protease inhibitors, such as lopinavir and ritonavir, are likely and could have clinically relevant consequences. Coadministration of drugs that enhance metabolization of antiretroviral drugs (for example, CYP3A4 inducers, such as bosentan) might lead to decreased plasma concentrations and, as a consequence, reduced efficacy and risk of viral resistance. Pharmacokinetic interactions are difficult to predict and the understanding of drug interactions between antiretroviral treatment in HIV infection and the treatment of comorbidities often found in HIV-infected patients is crucial.
The present study evaluated the interaction between bosentan and lopinavir/ritonavir in healthy individuals. The drugs were administered separately and in combination until steady-state conditions were attained.
Methods

Study participants
The Research Ethics Committee (Comité de Protection des Personnes Ouest IV, Centre Hospitalier Universitaire, Brest Cédex, France) reviewed and approved the study protocol and any material provided to the study participants. The study was conducted in full compliance with the principles of the Declaration of Helsinki.
A total of 12 healthy male participants (22-41 years of age) were recruited and all provided written informed consent. The sample size was based on power calculations derived from previous studies [12, 15] . Of them, eight were Caucasian and four were Black.
Participants were assessed to be healthy on the basis of screening examinations. Smoking, use of any drug (including over-the-counter and herbal medications, such as St John's wort) or the presence of any condition that might affect the pharmacokinetics of the study drugs were among the exclusion criteria.
Study design
This was a single centre open-label randomized threetreatment three-period crossover study. The participants were randomly assigned to one of six treatment sequences. All participants were to receive each of the following oral treatments every 12 h for 9 days to achieve steady-state conditions followed by a single dose in the morning of day 10: 125 mg bosentan alone (treatment A), lopinavir 400 mg/ritonavir 100 mg alone (treatment B) and the two in combination (treatment C). There was a washout period of ≥14 days between the treatment periods.
Blood sampling
Blood samples (2 ml) for determination of lopinavir, ritonavir, bosentan and bosentan metabolites (Ro 47-8634, Ro 48-5033 and Ro 64-1056) were collected into EDTA-containing tubes on days 1-9 before morning administration (trough) and on day 10, before and regularly until 12 h after administration.
Bioanalytical methods
Lopinavir and ritonavir were quantified in plasma using a validated automated online solid-phase extraction liquid chromatography-tandem mass spectrometry (LC-MS/MS) method [24] . The limit of quantification was set to 20.0 ng/ml for both analytes. Precision (%CV) of the assay was ≤7.9% for ritonavir and ≤8.4% for lopinavir. The accuracy of the assay was ≤6.1% for ritonavir and ≤4.7% for lopinavir.
Bosentan and metabolites were quantified in plasma using a validated LC-MS/MS method [25] . The limits of quantification were 2.0 ng/ml (bosentan) and 4.0 ng/ml (metabolites). The precision of the assays were ≤6.1% (bosentan), ≤5.3% (Ro 47-8634), ≤5.1% (Ro 48-5033) and ≤6.5% (Ro 64-1056). The accuracy of the assays were ≤10.2% (bosentan), ≤7.9% (Ro 47-8634), ≤3.5% (Ro 48-5033) and ≤5.3% (Ro 64-1056).
Analysis of pharmacokinetics and safety
Pharmacokinetic analysis was performed using Professional WinNonlin version 3.3 (Pharsight Corporation, Mountain View, CA, USA).
The area under the concentration-time curve during the 12 h dosing interval under steady-state conditions (AUC τ,ss ) on day 10 was calculated according to the linear trapezoidal rule. The maximum concentrations (C max,ss ) and the time at which they occurred (t max,ss ) were taken directly from the measured individual concentrations on day 10 of each treatment period. The trough concentrations (C trough ) were obtained on days 1-10 before administration of the morning dose.
Log-transformed C max,ss and AUC τ,ss values were analysed by a mixed-effect model (which is equivalent to a two-sided paired Student's t-test). Geometric mean ratios (GMRs) of combination treatment versus monotreatment and 90% confidence interval (CIs) were calculated from the corresponding back-transformed contrasts of the mixed-effect model.
Safety and tolerability end points (adverse events, changes from baseline in body weight, blood pressure, ECG variables and laboratory parameters) were analysed descriptively.
Results
A total of 12 participants were enrolled and treated in the study. All participants were evaluated for safety. Four participants were not included into the pharmacokinetic analysis as they discontinued treatment: three participants withdrew consent during or following treatment C because of severe treatment-emergent adverse events (headache in all three participants and associated vomiting in one participant) and one participant failed to return to the study centre.
Mean C trough on days 1-10 and mean plasma concentration-time profiles on day 10 (0-12 h in steady state) of lopinavir, ritonavir and bosentan given alone or in combination are shown in Figure 1 , Figure 2 and Figure 3 . C max,ss and AUC τ,ss of lopinavir, ritonavir and bosentan and its metabolites on day 10 are summarized in Table 1 . GMR and 90% CI are provided in Table 2 .
During the first four days, mean morning C trough values of lopinavir and ritonavir were higher than on days 8-10 and maximum C trough values were observed on day 4. Morning C trough values were slightly lower with coadministered bosentan ( Figure 1 and Figure 2) .
Bosentan did not affect C max,ss of lopinavir and ritonavir to a marked extent, with a GMR of 0.95 for lopinavir and 1.01 for ritonavir and the 90% CIs were within the range of 0.8-1.25 (Table 2) . AUC τ,ss of both lopinavir and ritonavir was slightly lower in the presence of bosentan compared with monotreatment (Table 1) : GMR (90% CI) was 0.86 (0.74-0.99) and 0.83 (0.76-0.92), respectively ( Table 2) .
With concomitant lopinavir/ritonavir treatment, C trough of bosentan increased markedly and reached a maximum on day 4 ( Figure 3 ). Trough levels subsequently decreased until steady-state conditions were apparently reached on day 8.
Coadministration of lopinavir/ritonavir led to an increased exposure to bosentan and its pharmacologically active metabolite, Ro 48-5033 ( Figure 3 and Table 1 ). AUC τ,ss values for bosentan and Ro 48-5033 were 5.2-and 4.9-fold higher than under bosentan monotreatment, and C max,ss values were 6.1-and 5.3-fold higher, respectively (Table 2 ). In the presence of lopinavir/ ritonavir, formation of the metabolite Ro 64-1056 was reduced to approximately 20% of the exposure under bosentan monotreatment and formation of Ro 47-8634 was almost completely inhibited. The 90% CI of the GMR of AUC τ,ss and C max,ss for bosentan, Ro 48-5033 and Ro 64-1056 were clearly outside the limits of 0.8-1.25 (Table 2) . Under bosentan treatment alone, 4 of 10 participants reported adverse events (mainly mild headache). Under treatment with lopinavir/ritonavir alone, six of nine participants reported adverse events (mainly mild to moderate gastrointestinal side effects, such as diarrhoea, abdominal pain or vomiting). The combination of bosentan and lopinavir/ritonavir was poorly tolerated. All 11 participants who received the combination reported at least one adverse event, altogether there were 42 events. All participants reported headache, starting on the first day of treatment and lasting 1-3 days in the majority of the participants. Gastrointestinal events were reported with a similar pattern as under lopinavir/ritonavir treatment; however, vomiting was reported 4 times under the combination treatment and only once under lopinavir/ ritonavir alone. The intensity of adverse events observed under combination treatment was mainly mild; however, 10 events of moderate intensity and 5 events of severe intensity were observed. In most events, the concomitant medication consisted of analgesics to treat mild to severe headache. Abnormalities in safety laboratory parameters were incidental and did not show treatment-related patterns. No increases in liver aminotransferase values were observed during the study. Under all three treatments, decreases in blood pressure were observed, with the most pronounced decrease under the combination treatment. No cases of clinically relevant hypotension were reported. ECG variables did not show clinically relevant abnormalities.
Discussion
In this study, it was shown that coadministration of bosentan, a CYP3A4 inducer, only slightly reduced the exposure to lopinavir and ritonavir, both substrates of CYP3A4. The observed effects on lopinavir and ritonavir pharmacokinetics were considered to be not clinically relevant. The pharmacokinetic parameters of lopinavir and ritonavir determined in this study were in close agreement with values reported previously [21, 26] . Coadministration of lopinavir/ritonavir and bosentan increased the exposure to bosentan at steady state by approximately fivefold. The 90% CI of the GMR for AUC τ,ss (3.84-7.10) and C max,ss (4.24-8.82) were completely outside the usually accepted no-effect boundaries of 0.8-1.25, indicating a drug-drug interaction. Similar results were observed for the pharmacologically active metabolite of bosentan, Ro 48-5033. Ro 47-8634 and Ro 64-1056, the formation of which is catalyzed by CYP3A4, were almost undetectable under lopinavir/ritonavir coadministration, likely because of the CYP3A4 inhibitory effects of ritonavir.
The effect of lopinavir/ritonavir on the pharmacokinetics of bosentan with a fivefold increase in exposure can only be partly explained by the inhibitory effect of ritonavir on CYP3A4 as ketoconazole, a strong inhibitor of CYP3A4, increased the exposure to bosentan only twofold [12] . Bosentan and its metabolite, Ro 48-5033, are OATP substrates [16] . Coadministration of bosentan and rifampicin, an inhibitor of OATP1B1 and OATP1B3, resulted in an initial increase in bosentan trough concentrations [13] . Considering that ritonavir has been shown to be a potent inhibitor of OATP1B1 [23] , a transporter-mediated drug-drug interaction could explain the increase in bosentan exposure.
The pharmacokinetic alterations were also reflected by an increase in adverse events, in particular mild to severe headache within the first 3 days of concomitant treatment, which were attributed to high systemic bosentan exposure. Overall, the combination treatment was poorly tolerated in healthy participants under the conditions of this study. In an open-label study with bosentan in patients with acquired immunodeficiency [3] , no special safety issues occurred. These patients had been titrated to 125 mg bosentan twice daily and were all on antiretroviral therapy. In this respect, the present study offered a worst-case scenario in which healthy participants initiated treatment with both lopinavir/ritonavir and bosentan concomitantly and, in addition, the full dose of bosentan was given from the start.
In conclusion, the present study has shown that bosentan does not affect lopinavir and ritonavir exposure to a clinically relevant extent and, therefore, dose adjustment of lopinavir/ritonavir might not be required.
The management of HIV-related PAH was recently reviewed [10] , which suggested an algorithm for treating patients with HIV-associated PAH based on data obtained from long-term clinical experience. The data of this and previous studies [3] suggest that the tolerability of coadministration of bosentan with protease inhibitors should be monitored, in particular at the beginning of the combined treatment phase.
The data observed for the combination of bosentan with ritonavir-boosted lopinavir might potentially be extrapolated to other ritonavir-boosted protease inhibitors.
